308 related articles for article (PubMed ID: 33968058)
1. Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?
García-Ríos E; Nuévalos M; Mancebo FJ; Pérez-Romero P
Front Immunol; 2021; 12():657144. PubMed ID: 33968058
[TBL] [Abstract][Full Text] [Related]
2. Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial.
Smith C; Beagley L; Rehan S; Neller MA; Crooks P; Solomon M; Holmes-Liew CL; Holmes M; McKenzie SC; Hopkins P; Campbell S; Francis RS; Chambers DC; Khanna R
Clin Infect Dis; 2019 Feb; 68(4):632-640. PubMed ID: 29982441
[TBL] [Abstract][Full Text] [Related]
3. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
4. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy.
Brestrich G; Zwinger S; Fischer A; Schmück M; Röhmhild A; Hammer MH; Kurtz A; Uharek L; Knosalla C; Lehmkuhl H; Volk HD; Reinke P
Am J Transplant; 2009 Jul; 9(7):1679-84. PubMed ID: 19459791
[TBL] [Abstract][Full Text] [Related]
5. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.
Molina-Ortega A; Martín-Gandul C; Mena-Romo JD; Rodríguez-Hernández MJ; Suñer M; Bernal C; Sánchez M; Sánchez-Céspedes J; Pérez Romero P; Cordero E
Clin Microbiol Infect; 2019 Jun; 25(6):753-758. PubMed ID: 30292792
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.
Haidar G; Boeckh M; Singh N
J Infect Dis; 2020 Mar; 221(Suppl 1):S23-S31. PubMed ID: 32134486
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients.
Amini L; Vollmer T; Wendering DJ; Jurisch A; Landwehr-Kenzel S; Otto NM; Jürchott K; Volk HD; Reinke P; Schmueck-Henneresse M
Front Immunol; 2019; 10():1148. PubMed ID: 31191530
[TBL] [Abstract][Full Text] [Related]
8. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
[TBL] [Abstract][Full Text] [Related]
9. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
Lemmermann NA; Reddehase MJ
Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus.
Pei XY; Zhao XY; Chang YJ; Liu J; Xu LP; Wang Y; Zhang XH; Han W; Chen YH; Huang XJ
J Infect Dis; 2017 Nov; 216(8):945-956. PubMed ID: 29029297
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.
Feuchtinger T; Opherk K; Bethge WA; Topp MS; Schuster FR; Weissinger EM; Mohty M; Or R; Maschan M; Schumm M; Hamprecht K; Handgretinger R; Lang P; Einsele H
Blood; 2010 Nov; 116(20):4360-7. PubMed ID: 20625005
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients.
Rowshani AT; Bemelman FJ; van Leeuwen EM; van Lier RA; ten Berge IJ
Transplantation; 2005 Feb; 79(4):381-6. PubMed ID: 15729162
[TBL] [Abstract][Full Text] [Related]
13. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
14. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro.
Greenberg PD; Reusser P; Goodrich JM; Riddell SR
Ann N Y Acad Sci; 1991 Dec; 636():184-95. PubMed ID: 1665321
[TBL] [Abstract][Full Text] [Related]
15. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
Walter EA; Greenberg PD; Gilbert MJ; Finch RJ; Watanabe KS; Thomas ED; Riddell SR
N Engl J Med; 1995 Oct; 333(16):1038-44. PubMed ID: 7675046
[TBL] [Abstract][Full Text] [Related]
16. Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors.
Beloki L; Ramírez N; Olavarría E; Samuel ER; Lowdell MW
Cytotherapy; 2014 Oct; 16(10):1390-408. PubMed ID: 24954783
[TBL] [Abstract][Full Text] [Related]
17. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
18. [Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation].
Xu Z; Huang X; Sun Y; Wang F; Yan C; Zhang X; Han W; Chen Y; Wang J; Chen H; Wang Y; Zhang Y; Liu K; Xu L
Zhonghua Nei Ke Za Zhi; 2015 Feb; 54(2):101-5. PubMed ID: 25907838
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials with CMV-specific T cells.
Peggs KS; Mackinnon S
Cytotherapy; 2002; 4(1):21-8. PubMed ID: 11953038
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.
Locatelli F; Bertaina A; Bertaina V; Merli P
Expert Rev Hematol; 2016 Nov; 9(11):1093-1105. PubMed ID: 27690683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
